Investigation of the Genetics of Hematologic Diseases

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Objective: * Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members, in conjunction with the existing St. Jude biorepository, to conduct genomic and functional studies to facilitate secondary objectives. Secondary

Objectives: * Utilize next generation genomic sequencing technologies to Identify novel genetic alternations that associate with disease status in individuals with unexplained non-malignant blood diseases. * Use genomic approaches to identify modifier genes in individuals with defined monogenic non-malignant blood diseases. * Use genomic approaches to identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease. * Use single cell genomics, transcriptomics, proteomics and metabolomics to investigate biomarkers for disease progression, sickle cell disease (SCD) pain events and the long-term cellular and molecular effects of hydroxyurea therapy. * Using longitudinal assessment of clinical and genetic, study the long-term outcomes and evolving genetic changes in non-malignant blood diseases. Exploratory Objectives * Determine whether analysis of select patient-derived bone marrow hematopoietic progenitor/stem (HSPC) cells or induced pluripotent stem (iPS) cells can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms. * Determine whether analysis of circulating mature blood cells and their progenitors from selected patients with suspected or proven genetic hematological disorders can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• An individual (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder, MDS or MPN.

• A biologically-related individual to the identified proband to include: first, second or third degree relatives.

Locations
United States
Tennessee
St. Jude Children's Research Hospital
RECRUITING
Memphis
Contact Information
Primary
Marcin Wlodarski, MD, PhD
referralinfo@stjude.org
866-278-5833
Time Frame
Start Date: 2016-06-17
Estimated Completion Date: 2050-07
Participants
Target number of participants: 1716
Treatments
Study Participants
Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
Authors
Marcin Wlodarski, Jeremie Estepp
Sponsors
Collaborators: Monroe Carell Jr. Children's Hospital at Vanderbilt, Boston Children's Hospital, Dana-Farber Cancer Institute, Children's Hospital of Philadelphia, University of Memphis, Baylor College of Medicine
Leads: St. Jude Children's Research Hospital

This content was sourced from clinicaltrials.gov